TG Therapeutics Inc TGTX
News
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseases
AMD, Kraft Heinz stocks surge, WeWork and CVS shares sink and other stocks on the move
TG Therapeutics' stock rockets after blowout earnings